ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Beximco Pharmaceuticals's annualizedNet Income for the quarter that ended in Dec. 2024 was $59.54 Mil.
Beximco Pharmaceuticals's average Total Assets over the quarter that ended in Dec. 2024 was $588.50 Mil. Therefore, Beximco Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2024 was 10.12%.
The historical rank and industry rank for Beximco Pharmaceuticals's ROA % or its related term are showing as below:
BXMPY'
s ROA % Range Over the Past 10 Years
Min: 5.41 Med: 6.78 Max: 10.02
Current: 8.95
During the past 13 years, Beximco Pharmaceuticals's highest ROA % was 10.02%. The lowest was 5.41%. And the median was 6.78%.
BXMPY's ROA % is not ranked
in the Drug Manufacturers industry.
Industry Median: 2.685
vs BXMPY: 8.95
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beximco Pharmaceuticals ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's ROA % distribution charts can be found below:
* The bar in red indicates where Beximco Pharmaceuticals's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2024) net income data.
ROA % is displayed in the 30-year financial page.
Beximco Pharmaceuticals (BXMPY) has a ROA % of 10.12% as of Dec. 2024. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Beximco Pharmaceuticals and its competitors. This is 49% above median its historical median of 6.78. Over the past decade, Beximco Pharmaceuticals' ROA % has ranged from 5.41 to 10.02.
Is Beximco Pharmaceuticals' ROA % too high?
Beximco Pharmaceuticals' current ROA % of 10.12% is 49% above median its 10-year median of 6.78. Over the past 10 years, this metric has ranged from a low of 5.41 to a high of 10.02. The Drug Manufacturers industry median ROA % is 2.69. Beximco Pharmaceuticals' value of 10.12% is 276.9% above this industry median. Overall, Beximco Pharmaceuticals has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' ROA % compare to ZTS and UTHR?
Beximco Pharmaceuticals' ROA % of 10.12% can be compared against companies in the Drug Manufacturers industry. The industry median ROA % is 2.69. Beximco Pharmaceuticals' value of 10.12% is 276.9% above this benchmark. Historically, Beximco Pharmaceuticals' own ROA % has ranged from 5.41 to 10.02 over the past decade. While the company's 10-year median is 6.78 vs. the industry median of 2.69, Beximco Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beximco Pharmaceuticals's current ROA % of 10.12% is 276.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Beximco Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beximco Pharmaceuticals's current ROA % is 10.12%, which is 49% above median its own 10-year median of 6.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Beximco Pharmaceuticals (BXMPY) has a current ROA % of 10.12%. The current ROA % is 10.12%, which is 49% above median its 10-year median of 6.78 and 276.9% above the Drug Manufacturers industry median of 2.69. Beximco Pharmaceuticals' overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Beximco Pharmaceuticals (BXMPY), the current ROA % is 10.12% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BXMPY has been successfully added to your 